

What Patients Should Do

- Talk to their doctor to find out what treatment is best for them.
- If a patient has had treatment for AF and symptoms continue, there is now a new therapy to consider, the Hybrid AF Therapy. It is important to speak to their doctor about treatment.
- It's important for each person to find an effective treatment that can stop atrial fibrillation, so that it doesn't progress and become worse.

EPI-Sense® Coagulation System/EPI-Sense ST™ Coagulation Device

U.S. Indications: The EPI-Sense Guided Coagulation System is intended for the treatment of symptomatic long-standing persistent atrial fibrillation (continuous atrial fibrillation greater than 12 months duration) when augmented in a hybrid procedure with an endocardial catheter listed in the instructions for use, in patients (1) who are refractory or intolerant to at least one Class I and/or III antiarrhythmic drug (AAD); and (2) in whom the expected benefit from rhythm control outweighs the potential known risks associated with a hybrid procedure such as delayed post-procedure inflammatory pericardial effusions. Contraindications include patients with Barrett's Esophagitis, left atrial thrombus, a systemic infection, active endocarditis, or a localized infection at the surgical site at the time of surgery. **Adverse Events:** Reported adverse events associated with epicardial ablation procedure may include, but are not limited to, the following: pericardial effusion/cardiac tamponade, pericarditis, excessive bleeding, phrenic nerve injury, stroke/TIA/neurologic complication. Please review the Instructions for Use for a complete listing of contraindications, warnings, precautions and potential adverse events located at the following AtriCure web address: <https://www.AtriCure.com/EPI-Sense-Coagulation-Device>. **Warnings:** Physicians should consider post-operative anti-inflammatory medication to decrease the potential for post-operative pericarditis. and/or delayed post-procedure inflammatory pericardial effusions. Physicians should consider post-procedural imaging (i.e. 1-3 weeks post-procedure) for detection of post-procedure inflammatory pericardial effusions. **Precautions:** Precautionary measures should be taken prior to considering treatment of patients: (1) Deemed to be high risk and who may not tolerate a potential delayed post-procedure inflammatory pericardial effusion. (2) Who may not be compliant with needed follow-ups to identify potential safety risks. To ensure patients undergoing treatment with the EPI-Sense device are well informed, the benefits, potential risks and procedural outcomes associated with the EPI-Sense Hybrid Convergent procedure should be discussed with the patient. Physicians should document accordingly in the medical record. Qualified operators are physicians authorized by their institution to perform surgical sub-xyphoid pericardial access. The coagulation devices should be used by physicians trained in the techniques of minimally invasive endoscopic surgical procedures and in the specific approach to be used. Operators should undergo training on the use of EPI-Sense device before performing the procedure. Safety and effectiveness of concomitant left atrial appendage closure was not evaluated in the CONVERGE study. Follow-up should be conducted at approximately 30 days post-procedure to monitor for signs of delayed onset pericarditis or pericardial effusion. **Rx Only**

Sources

1. Lloyd-Jones, D.M., et al. (2004). Lifetime risk for development of atrial fibrillation. *Circulation*, 110, 1042-1046. doi: 10.1161/01.CIR.0000140263.20897.42
2. Benjamin, E.J., et al. (2019). Heart Disease and Stroke Statistics — 2019 Update: A Report From the American Heart Association. *Circulation*, 139m e56-e528, DOI: 10.1161/CIR.0000000000000659
3. Rahman, F., et al. (2014). Global epidemiology of atrial fibrillation. *Nature reviews cardiology*, 11, 639-654. <https://doi.org/10.1038/nrcardio.2014.118>
4. Colilla, S. et al. (2013). Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. *American journal of cardiology*, 112(8), 1142-1147.
5. Zembala, M., et al. (2017). Staged hybrid ablation for persistent and longstanding persistent atrial fibrillation effectively restores sinus rhythm in long-term observation. *Archives of medical science : AMS*, 13(1), 109–117. <https://doi.org/10.5114/aoms.2015.53960>
6. DeLurgio, D.B., et al. (2021). Hybrid epicardial-endocardial RF ablation vs. endocardial catheter ablation for long-standing persistent atrial fibrillation treatment: Results from CONVERGE randomized controlled trial. International AF Symposium.
7. AtriCure. (2020). *PMA P200002 FDA Instructions For Use: Epi-Sense® Guided Coagulation System*.
8. Odotayo, A. et al. (2016). Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. *BMJ*, 354, i4482.
9. Calkins, H. et al. (2018). 2017 HRS/EHRA/ECAS/APHRs/SOLAECE Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation. *Heart rhythm*, 14(10):e275-444.
10. Barbarossa, A., et al. (2014). Silent atrial fibrillation: a critical review. *Journal of atrial fibrillation*, 7(3), 1138. http://www.jafib.com/PMC/XML/Inprogress/1138/1138pdf_federico_guerra.pdf.